Revenue segments as reported by the company.

Net revenue, before excise taxes

Excise taxes

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

Research and development

General and administrative

Restructuring costs

Share-based payments

Depreciation and amortization

Impairment loss on goodwill and indefinite-lived intangible assets

Impairment loss on long-lived assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cronos Group

Cronos Group, Inc. engages in the production and distribution of cannabis. Its brands include PEACE NATURALS, COVE, Spinach, Lord Jones, and PEACE+. The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cronos Group, Inc. engages in the production and distribution of cannabis. I It operates through the Canada and Israel segments. The company was founded on August 21, 2012 and is headquartered in Toronto, Canada.

Cronos shares peaked months ago at $24 and its latest Q1 report failed to attract buyers. But there are still reasons to be optimistic.

Cronos Stock Peaked But It Still Holds Promise

Wall Street has handed out not one, two, or three... but seven price-target cuts to this marijuana stock since the month began.

This Pot Stock Has Turned Into Wall Street's Pinata

Instead of acquiring additional production, Cronos may choose to fortify the strongest aspect of its business.

Could This Be Cronos Group's Most Logical Acquisition Target?

Medifast

Cronos Group Inc. CRON, -7.47% CRON, -6.34% announced Tuesday a supply deal with MediPharm Labs Corp.

Cronos, MediPharm enter supply deal for private-label cannabis concentrate

Aurora Cannabis

Altria

Though perfectly legal, these accounting tricks are masking the true operating results of many pot stocks.

3 Ways Marijuana Stocks Are Tricking Investors

Aphria

Canopy Growth

CannTrust Holdings

HEXO Corp

Tilray Brands

Some Canadian marijuana growers are deceivingly cheap, while others appear downright avoidable.

Which Pot Stocks Are the Cheapest Relative to 2020 Sales?

Much like its previous quarterly report, pot stock Cronos Group's first quarter creates all the wrong buzz.

Cronos Group Wraps Up Another Laughably Bad Quarter

Village Farms International

Production efficiency isn't a strong suit for these marijuana growers.

These 4 Pot Stocks Have Surprisingly Poor Crop Yields

According to the company, there's plenty of growth just a bit further ahead.

Is Cronos Group a Buy on the Dip?

Investors were less than thrilled by the performance generated by Cronos for the company's latest quarter.

Cronos Group Deserves Another Chance

Scotts Miracle-Gro

Cannabis stocks had a huge showing on Wall Street this past fall. In fact, most of the news flow surrounding these stocks had investors pouring money into them.

Short Sellers Get Higher on Cannabis Stocks

Here's what you should know about this fast-growing cannabis company following its latest quarterly financial results.

Marijuana Stocks: 7 Facts About Cronos Group's Quarterly Earnings

Roku

Trade worries rattled the market, but Roku soared on strong growth. Results from marijuana stock Cronos failed to impress investors.

What Happened in the Stock Market Today: Cronos & Roku

Investors didn't like what they saw with the Canadian marijuana producer's Q1 update.

Why Cronos Group Stock Sank Today

The Canadian marijuana producer reported seemingly great results in Q1. So why did its stock fall?

Cronos Group Blew Past Revenue and Earnings Estimates in Q1 -- Here's Why No One Is Excited

Cronos Group, Inc. (CRON) CEO Mike Gorenstein on Q1 2019 Results - Earnings Call Transcript

Canadian cannabis company Cronos Group Inc (NASDAQ: CRON) reported first-quarter results Thursday that included revenue growth of 120 percent on the year driven by legalization of adult-use cannabis and strong CBD oil sales.

Cronos Group More Than Doubles Revenue, Sales Volume In Q1

Cronos (CRON) delivered earnings and revenue surprises of 1900.00% and 3.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Cronos Group (CRON) Q1 Earnings and Revenues Surpass Estimates

Canadian cannabis company Cronos Group Inc. said Thursday it had income of C$427,812 ($317,380), or 17 cents a share, in the first quarter, after a loss of C$1,085, or 1 cent a share, in the year-earlier period.

Cronos swings to small profit in Q1 as revenue climbs

The Cronos earnings report was weaker than expected, with a wider loss and revenue not strong enough. Cronos shares fell.

Cronos Group Reports Wider Loss, Revenue Miss

Cronos may have the third-largest market cap of any pot stock, but it's not the major player it's being made out to be.

A Crazy, but True, Fact About Cronos Group That Investors Need to Know

The much-maligned Canadian marijuana producer reports its Q1 financial results on Thursday. Here are three things to look for.

What You Can Expect in Cronos Group's Q1 Earnings Update

Cronos Group Inc. said Tuesday that it's expanding its research and development program by opening a facility in Israel that will be focused on cannabinoid devices.

Cronos Group Opens Cannabinoid Device R&D Center In Israel

Apart from the regular top and bottom-line numbers, investors will focus on Cronos' (CRON) pipeline progress, when it reports Q1 results.

Will Higher Expenses Dent Cronos' (CRON) Earnings in Q1?

Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.

News for Cronos Group Stock (CRON)